International Journal of Endocrinology / 2016 / Article / Tab 2

Clinical Study

Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial

Table 2

Pharmacokinetic parameters.

Pharmacokinetic parametersMedian (range) value (Mann–Whitney)
TAXVPA + TAX

(ng/mL)1155 (767–1749)1134 (608–1565)0.85
AUC (ng h/mL)3490 (2177–4321)3434 (2050–4137)0.68
(1/h)0.34 (0.18–0.56)0.49 (0.41–0.56)0.05
(h)2.03 (1.24–3.94)1.42 (1.25–1.69)0.05
Cl (mL/h)39858 (30189–71196)41819 (30898–71012)0.91
(mL)52138 (43138–147388)61452 (34164–142622)0.58

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.